Results for Lu-Dotatate in Patients With Midgut NETs Continue to Impress

January 19, 2016

For patients with advanced midgut neuroendocrine tumors (NETs), the peptide receptor radionuclide therapy Lu-Dotatate (Lutetium-177 DOTATATE; Lutathera) continues to confer a major therapeutic benefit, reducing the risk of disease progression or death by 79% and signaling an improvement in overall survival as well. 

This update from the randomized phase III NETTER-1 trial also showed that the therapy was “quite well-tolerated,” according to lead author Jonathan R. Strosberg, MD, a medical oncologist with Moffitt Cancer Center, who presented the results during a presscast at the 2016 Gastrointestinal (GI) Cancers Symposium to be held January 21-23 in San Francisco, California. 

Read the full article.